<?xml version="1.0" encoding="UTF-8"?>
<p id="Par86">In PID patients, investigation for SARS-CoV-2 is recommended after public exposure and when acute respiratory or gastrointestinal symptoms occur. After exposure to SARS-CoV-2 in PID patients, the risk/benefits of continuing immunosuppressive or immunomodulatory therapy should be discussed with the immunology specialist.</p>
